Key Developments For Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences, Inc. (OCLS.O) (Consolidated Issue listed on NASDAQ Capital Market)
Oculus Innovative Sciences, Inc.' Development Partner Bayer Animal Health, Receives Regulatory Approvals To Market Microcyn-Based Vetericyn Animal Healthcare Products In China And Taiwan
Oculus Innovative Sciences, Inc. announced that its development partners, Bayer Animal Health divisions in China and Taiwan, recently secured regulatory approvals in both those countries to develop and market Microcyn-based Vetericyn products for their respective animal healthcare markets. While the regulatory approvals closely coincide in terms of timing, they were separately facilitated; the Chinese review and approval by Bayer (Sichuan) Animal Health Co. Ltd. as the result of a development agreement entered into in June 2008, and the Taiwanese approval by Bayer Taiwan Co. Ltd. as the result of a December 2008 agreement. In both instances, the approvals are for the use of Vetericyn animal healthcare products in both companion and food animals. As provided by the development agreements, Bayer has first right of negotiation to enter into distribution agreements for Oculus` Vetericyn animal brands for both China and Taiwan. Those negotiations, in part to determine pricing and minimum purchases, are now underway. Bayer HealthCare, a subsidiary of Bayer AG.
Oculus Innovative Sciences, Inc. Announces New Partnership Agreement with V&M Industries, Inc. For Microcyn-Based OTC Human Wound Care Products
Oculus Innovative Sciences, Inc. announced that it has entered into a new strategic partnership with V&M Industries, Inc. for non-exclusive rights to market Microcyn-based skin and wound care over-the-counter products in the United States and Canada while providing the Company with a significant percentage of those revenues.
Oculus Innovative Sciences, Inc. Reaffirms FY 2013 Guidance
Oculus Innovative Sciences, Inc. reaffirmed fiscal 2013 guidance to achieve annual revenue of $45 to $60 million with operating profitability of 20%.
Oculus Innovative Sciences, Inc. Announces Securities Offering Up To 1.9 Million Shares of Common Stock
Oculus Innovative Sciences, Inc. announced an offering to sell securities to selected investors of up to 1.9 million shares of common stock. The offering is made pursuant to a registration statement that was filed by Oculus with the Securities and Exchange Commission (the SEC) and declared effective by the SEC on July 24, 2009. The offering is expected to close on or about July 30, 2009. The securities are being offered in units and will include up to 1.9 million shares of Oculus common stock and warrants to purchase up to 950,000 shares of Oculus common stock. The warrants will have a maturity of five years and an exercise price that will be at a premium to the market. Dawson James Securities is acting as exclusive placement agent for the offering.
Oculus Innovative Sciences, Inc. Introduces First Microcyn-Based Product For Mexican Consumer Market
Oculus Innovative Sciences, Inc. announced that it has introduced its first consumer product for the Mexican market, a consumer-sized 120-milliliter bottle of Microdacyn60, a topical antiseptic approved by the Mexican Ministry of Health for the treatment of wounds and infections.
